1887

Abstract

Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the monoclonal antibody H16.V5. To investigate the importance of this epitope for overall immunogenicity of HPV-16, HPV-16 virus-like particles devoid of the H16.V5 epitope were engineered by site-directed mutagenesis of ten non-conserved, surface-exposed residues. Removal of the H16.V5-defined epitope had only a marginal effect on antigenic reactivity with antibodies in sera from infected subjects, but affected immunogenicity in experimental immunization of mice, with reduced induction of both antibody responses and CTL responses.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82449-0
2007-03-01
2019-11-15
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/3/792.html?itemId=/content/journal/jgv/10.1099/vir.0.82449-0&mimeType=html&fmt=ahah

References

  1. Andersson-Ellstrom, A., Dillner, J., Hagmar, B., Schiller, J., Sapp, M., Forssman, L. & Milsom, I. ( 1996; ). Comparison of development of serum antibodies to HPV16 and HPV33 and acquisition of cervical HPV DNA among sexually experienced and virginal young girls. A longitudinal cohort study. Sex Transm Dis 23, 234–238.[CrossRef]
    [Google Scholar]
  2. Bosch, F. X. & de Sanjosé, S. ( 2003; ). Chapter 1: Human papillomavirus and cervical cancer – burden and assessment of causality. J Natl Cancer Inst Monogr 31, 3–13.
    [Google Scholar]
  3. Bosch, F. X., Manos, M. M., Muñoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R. & Shah, K. V. ( 1995; ). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 87, 796–802.[CrossRef]
    [Google Scholar]
  4. Brown, D. R., Fife, K. H., Wheeler, C. M., Koutsky, L. A., Lupinacci, L. M., Railkar, R., Suhr, G., Barr, E. & Dicello, A. ( 2004; ). Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22, 2936–2942.[CrossRef]
    [Google Scholar]
  5. Carter, J. J., Wipf, G. C., Benki, S. F., Christensen, N. D. & Galloway, D. A. ( 2003; ). Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol 77, 11625–11632.[CrossRef]
    [Google Scholar]
  6. Carter, J. J., Wipf, G. C., Madeleine, M. M., Schwartz, S. M., Koutsky, L. A. & Galloway, D. A. ( 2006; ). Identification of human papillomavirus type 16 L1 surface loops required for neutralization by human sera. J Virol 80, 4664–4672.[CrossRef]
    [Google Scholar]
  7. Chackerian, B., Lenz, P., Lowy, D. R. & Schiller, J. T. ( 2002; ). Determinants of autoantibody induction by conjugated papillomavirus virus-like particles. J Immunol 169, 6120–6126.[CrossRef]
    [Google Scholar]
  8. Chen, X. S., Garcea, R. L., Goldberg, I., Casini, G. & Harrison, S. C. ( 2000; ). Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5, 557–567.[CrossRef]
    [Google Scholar]
  9. Christensen, N. D., Hopfl, R., DiAngelo, S. L., Cladel, N. M., Patrick, S. D., Welsh, P. A., Budgeon, L. R., Reed, C. A. & Kreider, J. W. ( 1994; ). Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 75, 2271–2276.[CrossRef]
    [Google Scholar]
  10. Christensen, N. D., Cladel, N. M., Reed, C. A., Budgeon, L. R., Embers, M. E., Skulsky, D. M., McClements, W. L., Ludmerer, S. W. & Jansen, K. U. ( 2001; ). Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291, 324–334.[CrossRef]
    [Google Scholar]
  11. Clifford, G. M., Smith, J. S., Plummer, M., Muñoz, N. & Franceschi, S. ( 2003; ). Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 88, 63–73.[CrossRef]
    [Google Scholar]
  12. Da Silva, D. M., Pastrana, D. V., Schiller, J. T. & Kast, W. M. ( 2001; ). Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines. Virology 290, 350–360.[CrossRef]
    [Google Scholar]
  13. De Bruijn, M. L., Greenstone, H. L., Vermeulen, H., Melief, C. J., Lowy, D. R., Schiller, J. T. & Kast, W. M. ( 1998; ). L1-specific protection from tumor challenge elicited by HPV16 virus-like particles. Virology 250, 371–376.[CrossRef]
    [Google Scholar]
  14. de Villiers, E. M., Fauquet, C., Broker, T. R., Bernard, H. U. & zur Hausen, H. ( 2004; ). Classification of papillomaviruses. Virology 324, 17–27.[CrossRef]
    [Google Scholar]
  15. Dillner, L., Heino, P., Moreno-Lopez, J. & Dillner, J. ( 1991; ). Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses. J Virol 65, 6862–6871.
    [Google Scholar]
  16. Drobni, P., Mistry, N., McMillan, N. & Evander, M. ( 2003; ). Carboxy-fluorescein diacetate, succinimidyl ester labeled papillomavirus virus-like particles fluoresce after internalization and interact with heparan sulfate for binding and entry. Virology 310, 163–172.[CrossRef]
    [Google Scholar]
  17. Dupuy, C., Buzoni-Gatel, D., Touze, A., Le Cann, P., Bout, D. & Coursaget, P. ( 1997; ). Cell mediated immunity induced in mice by HPV 16 L1 virus-like particles. Microb Pathog 22, 219–225.[CrossRef]
    [Google Scholar]
  18. Emini, E. A., Hughes, J. V., Perlow, D. S. & Boger, J. ( 1985; ). Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol 55, 836–839.
    [Google Scholar]
  19. Ferenczy, A. & Franco, E. ( 2002; ). Persistent human papillomavirus infection and cervical neoplasia. Lancet Oncol 3, 11–16.[CrossRef]
    [Google Scholar]
  20. Fife, K. H., Wheeler, C. M., Koutsky, L. A., Barr, E., Brown, D. R., Schiff, M. A., Kiviat, N. B., Jansen, K. U. & Barber, H. ( 2004; ). Dose-ranging studies of the safety and immunogenicity of human papillomavirus Type 11 and Type 16 virus-like particle candidate vaccines in young healthy women. Vaccine 22, 2943–2952.[CrossRef]
    [Google Scholar]
  21. Giroglou, T., Florin, L., Schafer, F., Streeck, R. E. & Sapp, M. ( 2001; ). Human papillomavirus infection requires cell surface heparan sulfate. J Virol 75, 1565–1570.[CrossRef]
    [Google Scholar]
  22. Harper, D. M., Franco, E. L., Wheeler, C., Ferris, D. G., Jenkins, D., Schuind, A., Zahaf, T., Innis, B. & Naud, P. ( 2004; ). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364, 1757–1765.[CrossRef]
    [Google Scholar]
  23. Hopp, T. P. & Woods, K. R. ( 1981; ). Prediction of protein antigenic determinants from amino acid sequences. Proc Natl Acad Sci U S A 78, 3824–3828.[CrossRef]
    [Google Scholar]
  24. Jameson, B. A. & Wolf, H. ( 1988; ). The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci 4, 181–186.
    [Google Scholar]
  25. Joyce, J. G., Tung, J.-S., Przysiecki, C. T., Cook, J. C., Lehman, E. D., Sands, J. A., Jansen, K. U. & Keller, P. M. ( 1999; ). The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem 274, 5810–5822.[CrossRef]
    [Google Scholar]
  26. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R. & Schiller, J. T. ( 1992; ). Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89, 12180–12184.[CrossRef]
    [Google Scholar]
  27. Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M. & Jansen, K. U. ( 2002; ). A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347, 1645–1651.[CrossRef]
    [Google Scholar]
  28. Le Cann, P., Coursaget, P., Iochmann, S. & Touze, A. ( 1994; ). Self-assembly of human papillomavirus type 16 capsids by expression of the L1 protein in insect cells. FEMS Microbiol Lett 117, 269–274.[CrossRef]
    [Google Scholar]
  29. Liu, W. J., Liu, X. S., Zhao, K. N., Leggatt, G. R. & Frazer, I. H. ( 2000; ). Papillomavirus virus-like particles for the delivery of multiple cytotoxic T cell epitopes. Virology 273, 374–382.[CrossRef]
    [Google Scholar]
  30. Longworth, M. S. & Laimins, L. A. ( 2004; ). Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev 68, 362–372.[CrossRef]
    [Google Scholar]
  31. Modis, Y., Trus, B. L. & Harrison, S. C. ( 2002; ). Atomic model of the papillomavirus capsid. EMBO J 21, 4754–4762.[CrossRef]
    [Google Scholar]
  32. Munger, K., Baldwin, A., Edwards, K. M., Hayakawa, H., Nguyen, C. L., Owens, M., Grace, M. & Huh, K. ( 2004; ). Mechanisms of human papillomavirus-induced oncogenesis. J Virol 78, 11451–11460.[CrossRef]
    [Google Scholar]
  33. Nieland, J. D., Da Silva, D. M., Velders, M. P., de Visser, K. E., Schiller, J. T., Muller, M. & Kast, W. M. ( 1999; ). Chimeric papillomavirus virus-like particles induce a murine self-antigen-specific protective and therapeutic antitumor immune response. J Cell Biochem 73, 145–152.[CrossRef]
    [Google Scholar]
  34. Revaz, V., Benyacoub, J., Kast, W. M., Schiller, J. T., De Grandi, P. & Nardelli-Haefliger, D. ( 2001; ). Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice. Virology 279, 354–360.[CrossRef]
    [Google Scholar]
  35. Roden, R. B., Armstrong, A., Haderer, P., Christensen, N. D., Hubbert, N. L., Lowy, D. R., Schiller, J. T. & Kirnbauer, R. ( 1997; ). Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 71, 6247–6252.
    [Google Scholar]
  36. Roden, R. B., Ling, M. & Wu, T.-C. ( 2004; ). Vaccination to prevent and treat cervical cancer. Hum Pathol 35, 971–982.[CrossRef]
    [Google Scholar]
  37. Rudolf, M. P., Nieland, J. D., DaSilva, D. M., Velders, M. P., Muller, M., Greenstone, H. L., Schiller, J. T. & Kast, W. M. ( 1999; ). Induction of HPV16 capsid protein-specific human T cell responses by virus-like particles. Biol Chem 380, 335–340.
    [Google Scholar]
  38. Ruedl, C., Schwarz, K., Jegerlehner, A., Storni, T., Manolova, V. & Bachmann, M. F. ( 2005; ). Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 79, 717–724.[CrossRef]
    [Google Scholar]
  39. Sadeyen, J. R., Tourne, S., Shkreli, M., Sizaret, P. Y. & Coursaget, P. ( 2003; ). Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduces their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope. Virology 309, 32–40.[CrossRef]
    [Google Scholar]
  40. Shank-Retzlaff, M., Wang, F., Morley, T., Anderson, C., Hamm, M., Brown, M., Rowland, K., Pancari, G. & Zorman, J. ( 2005; ). Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil vaccine samples. Hum Vaccin 1, 191–197.[CrossRef]
    [Google Scholar]
  41. Slupetzky, K., Shafti-Keramat, S., Lenz, P., Brandt, S., Grassauer, A., Sara, M. & Kirnbauer, R. ( 2001; ). Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 82, 2799–2804.
    [Google Scholar]
  42. Touze, A., El Mehdaoui, S., Sizaret, P.-Y., Mougin, C., Muñoz, N. & Coursaget, P. ( 1998; ). The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system. J Clin Microbiol 36, 2046–2051.
    [Google Scholar]
  43. Villa, L. L., Ault, K. A., Giuliano, A. R., Costa, R. L., Petta, C. A., Andrade, R. P., Brown, D. R., Ferenczy, A. & Harper, D. M. ( 2006; ). Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18. Vaccine 24, 5571–5583.[CrossRef]
    [Google Scholar]
  44. Wakabayashi, M. T., Da Silva, D. M., Potkul, R. K. & Kast, W. M. ( 2002; ). Comparison of human papillomavirus type 16 L1 chimeric virus-like particles versus L1/L2 chimeric virus-like particles in tumor prevention. Intervirology 45, 300–307.[CrossRef]
    [Google Scholar]
  45. Wang, Z., Christensen, N., Schiller, J. T. & Dillner, J. ( 1997; ). A monoclonal antibody against intact human papillomavirus type 16 capsids blocks the serological reactivity of most human sera. J Gen Virol 78, 2209–2215.
    [Google Scholar]
  46. Wang, X., Wang, Z., Christensen, N. D. & Dillner, J. ( 2003; ). Mapping of human serum-reactive epitopes in virus-like particles of human papillomavirus types 16 and 11. Virology 311, 213–221.[CrossRef]
    [Google Scholar]
  47. White, W. I., Wilson, S. D., Palmer-Hill, F. J., Woods, R. M., Ghim, S. J., Hewitt, L. A., Goldman, D. M., Burke, S. J. & Jenson, A. B. ( 1999; ). Characterization of a major neutralizing epitope on human papillomavirus type 16 L1. J Virol 73, 4882–4889.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82449-0
Loading
/content/journal/jgv/10.1099/vir.0.82449-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error